Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators

Sponsor
University Magna Graecia (Other)
Overall Status
Completed
CT.gov ID
NCT00743080
Collaborator
Johnson & Johnson (Industry)
1
2
24

Study Details

Study Description

Brief Summary

To date, laparoscopic approach may apply to several gynecologic diseases. Among the recent advances in laparoscopy an important role was assumed by the methods of tissue extraction. In particular electronic power morcellators have become instruments of large use in surgical practice.

The tissue morcellator is an endoscopic instrument indicated for cutting, coring and extracting tissue in operative laparoscopy, and it has a pivotal role during specific gynaecologic procedures as well as myomectomy and hysterectomy. The main advantages offered by electronic morcellator consist in reduction of operative time and of risk in hernia formation, this last due to the absence of fascia's tearing or stretching.

Recently, a new generation of tissue morcellator has been commercialized. In particular, GYNECARE MORCELLEX (Ethicon-Johnson & Johnson Gateway, US) and ROTOCUT G1 (Karl Storz, Culver City, CA, US) are two tissue morcellators currently available. These instruments seem to offer advantages over the previous models in terms of precision, speed and durability. The most useful of this features seems to be the higher speed, in particular it has been calculated that they morcellate tissues approximately four times faster than those of the previous generation. The high speed that characterizes this new morcellator potentially results in reduced operative time with consequent benefits in other surgical outcomes such as postoperative pain and recovery time.

Even if both morcellator seems to be high-quality instruments, no study was designed until now to compare these two tools in a prospective fashion.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX
  • Procedure: Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1
Phase 4

Detailed Description

Patients with symptomatic uterine leiomyomas will be assessed for eligibility and will be enrolled in the present protocol-study.

At entry, in each woman age, parity, body mass index (BMI), menopausal, socioeconomic and work status, symptoms related to the gynecologic disease, previous major surgical laparotomies, and associated medical condition will be assessed.

All eligible patients will be randomized in single blocks using a central computer generating randomization lists (University of Catanzaro). The subjects will be assigned to one of four subgroups of surgical treatment, i.e. group A1 myomectomies performed using GYNECARE MORCELLEX, group A2 supracervical hysterectomies performed using GYNECARE MORCELLEX, group B1 myomectomies performed using ROTOCUT G1 and group B2 supracervical hysterectomies performed using ROTOCUT G1.

Before surgery, for each patient gynaecological and rectal examination, Papanicolau smear test, ultrasonographic and hysteroscopic assessment with endometrial biopsy will be performed.

For each surgical intervention the following parameters will be recorded: duration of surgical procedures, intra-operative blood loss, amount of blood transfusion, intra-operative complications, number of laparotomic conversion, postoperative pain, post-operative complications, hospital stay, and time to return to full activity and/or work.

Data will be analyzed using the intention-to-treat principle and a P value of 0.05 or less will be considered significant.

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study
Study Start Date :
Jan 1, 2008
Study Completion Date :
Jan 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

Laparoscopic myomectomy and supracervical hysterectomy using GYNECARE MORCELLEX

Procedure: Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX
Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX). Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation.

Active Comparator: 2

Laparoscopic myomectomy and supracervical hysterectomy using ROTOCUT G1

Procedure: Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1
Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1). Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation.

Outcome Measures

Primary Outcome Measures

  1. Morcellament time []

Secondary Outcome Measures

  1. Total operative time []

  2. Feasibility [subjective score of difficulty] []

  3. Blood loss []

  4. Post-operative complications [12 months]

  5. Postoperative pain []

  6. Hospital stay []

  7. Time to return to full activity and/or work [12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Symptomatic uterine leiomyomas with main diameter over 5 cm
Exclusion Criteria:
  • Major medical conditions

  • Endocrinologic diseases

  • Current or past, acute or chronic psychiatric disorders

  • Premenstrual syndrome

  • Use of drugs influencing cognition, vigilance and/or mood within six months of the study enrolment

  • Hypoechoic or calcified leiomyomas at ultrasound

  • Associated lesions in the uterus and adnexa at ultrasound

  • Pattern of hyperplasia with cytologic atypia in the endometrial biopsy

  • Abnormal Papanicolau smear test

  • Positive urine pregnancy test result

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Magna Graecia Catanzaro Italy 88100

Sponsors and Collaborators

  • University Magna Graecia
  • Johnson & Johnson

Investigators

  • Principal Investigator: Fulvio Zullo, MD, PhD, Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, - Viale Europa Loc. Germaneto 88100 Catanzaro, Italy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00743080
Other Study ID Numbers:
  • 300-07-015
First Posted:
Aug 28, 2008
Last Update Posted:
Nov 3, 2010
Last Verified:
Aug 1, 2008

Study Results

No Results Posted as of Nov 3, 2010